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The need for mouse models, with their well-developed genetics and similarity to human physiology and anatomy, is clear and their
central role in furthering our understanding of human disease is readily apparent in the literature. Mice carrying mutations that
alter developmental pathways or cellular function provide model systems for analyzing defects in comparable human disorders
and for testing therapeutic strategies. Mutant mice also provide reproducible, experimental systems for elucidating pathways of
normaldevelopmentandfunction.Twoprograms,theEyeMutantResourceandtheTranslationalVisionResearchModels,focused
on providing such models to the vision research community are described herein. Over 100 mutant lines from the Eye Mutant
Resource and 60 mutant lines from the Translational Vision Research Models have been developed. The ocular diseases of the
mutant lines include a wide range of phenotypes, including cataracts, retinal dysplasia and degeneration, and abnormal blood
vessel formation. The mutations in disease genes have been mapped and in some cases identiﬁed by direct sequencing. Here, we
report 3 novel alleles of Crxtvrm65, Rp1tvrm64,a n dRpe65tvrm148 as successful examples of the TVRM program, that closely resemble
previously reported knockout models.
1.Introduction
The Eye Mutant Resource (EMR) and the Translational
Vision Research Models (TVRMs) programs currently
housed at The Jackson Laboratory are tailored to provide
genetically deﬁned models of vision-associated diseases to
the Research Community. The EMR screens for spontaneous
mutations in the large production and repository colonies,
while the TVRM program screens for chemically induced
mutationsinthird-generation(G3)oﬀspringofmutagenized
mice. Both programs are motivated by the need for well-
characterized models for studying the function of particular
molecules in the eye, for examining disease pathology, and
for providing a resource to test therapeutic regimens.
In the early phases of the EMR program, the tools for
examining mice for ocular abnormalities were adapted for
the small size of the mouse eye [1, 2]. These tools included
indirect ophthalmoscopy, slit lamp biomicroscopy, fundus
photography, and electroretinography (ERG). Initially, mice
from various stocks and inbred strains were screened to
identify spontaneous ocular mutants using the ﬁrst two
methodologies. Currently, ERG screening is done as well to
identify and characterize new retinal mutants. As secondary
screens, ﬂuorescein angiography is used to detect vascular
changes [2], and noninvasive tonometry [3] is used to
assess changes in intraocular pressure. Screening has also
been expanded to include genetically engineered strains
from the Jackson Laboratory’s Genetic Resource Sciences
(GRS)repositorythataresystematicallyexaminedastheyare
removed from the shelf or are retired from breeding. Also, in
addition to the initial phenotypic characterization, the EMR
strives to identify the mutations underlying the disorders.
Systematic chemical mutagenesis screens have been suc-
cessfully carried out in several model organisms, including
Drosophila [4], C. elegans [5], and zebraﬁsh [6, 7]. The
zebraﬁsh screens have provided valuable eye models, espe-
cially those pertaining to eye development [8]. In addition
to our eﬀorts, other mutagenesis screens for eye phenotypes
in mice have been reported in which a number of mutants
have been described [9–11]. Although diﬀerent methods for
mutagenizing mice are available, the alkylating agent, N-
ethyl-N-nitrosourea (ENU), is the mutagen most commonly2 Journal of Ophthalmology
used [12]. ENU mainly induces point mutations resulting
in a range of consequences including total or partial loss-
of-function, dominant-negative, or gain-of-function alleles
[13–16]. Its eﬀectiveness as a mutagen is dependent on
dosage, frequency of administration, and mouse strain.
Eﬀectiveness, in terms of identifying mutants, depends upon
the type of screen (e.g., dominant versus recessive) and
the reproducibility of the phenotypic assay utilized. Mutant
recovery has ranged from a rate of 1/175 [17], to ∼1/666 in
Speciﬁc Locus Tests (SLTs) [12], and to an average of 1/1470
based on recessive screening in a deﬁned chromosomal
region [18]. The mutation rates for individual loci can vary
by almost tenfold [12, 17, 18].
The majority of large-scale mutagenesis screens have
been dominant screens. This is probably due to the relative
ease of creating mutagenized mice for dominant screens
compared to recessive ones. Screening for dominants on a
genome-wide basis can be done in one generation (G1),
while recessives generally require three. The Neuherburg
Cataract Mutant Collection of ∼170 dominant mutants was
assembled through screening over 500,000 ﬁrst-generation
mice exposed to various mutagens [19]. The GSF-Munich
[14] and MRC-Harwell [13, 20] programs were established
using a phenotype-based approach to screen thousands
of mice for dominant mutations aﬀecting a variety of
biological processes. A major drawback to dominant screens,
however, is that not all mutations have dominant eﬀects. A
dominant screen will, therefore, miss many of the induced
mutations. Estimates suggest that the frequency of diseases
caused by recessive mutations is 4–10-fold higher than for
dominant ones. In fact, of 218 eye mutants surveyed in the
Mouse Genome Informatics Database, 80% were recessive
mutations and only 20% were dominant or semidominant.
Therefore, the TVRM program screened a G3 population of
mutagenized mice for recessive mutations.
Screening for spontaneous and chemically induced
mutantsprovidesanimportantsourceofmodelstostudythe
eﬀects of single-gene mutations found in human patients.
Additionally, new mutations within the same gene provide
allelic series in which splice variants or domain-speciﬁc
eﬀects can be queried. Finally, mutations in novel genes that
lead to retinal disorders can be discovered using a forward
genetic approach.
2.MaterialsandMethods
2.1. Origins of Mice and Husbandry. The ages at which the
visual system is aﬀected by disease can vary considerably.
For the EMR program, an initial screen of JAX Mice &
Services(JMSs)productioncoloniesandmiceremovedfrom
the GRS Repository is routinely performed at ∼2 months
of age and if necessary, additional screening is done at
an older age, usually at 6 months of age. Also, as with
other neuronal diseases, diseases of the visual system are
not reversible, so ocular diseases can be captured in retired
breeders. Therefore, when available, retired breeders that are
olderthan1yearofagearescreened.C57BL/6J(B6)G3ENU
mutagenized mice were screened by the TVRM program. For
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Figure 1: Schematic representation of the mating scheme of domi-
nant (G1) or recessive (G3) screens. Male mice were mutagenized (3
weekly doses, 80mg/kg) and mated to WT females after 4 weeks. If
any female was pregnant within 5 weeks, the mating was discarded.
If,however,malemiceimpregnatedafemaleafterthat,theresulting
G1 males were crossed to their respective female counterparts, and
the G2 progeny were backcrossed to the G1 fathers to generate G3
oﬀspring.
the chemically induced mutations, ENU was administered
to male B6 mice in three weekly injections of 80mg/kg. G3
oﬀspring were generated using a three-generation backcross
matingscheme(Figure 1).G3micewerescreenedat24weeks
of age in order to enhance our ability to identify late onset
diseases.
To determine if the disease phenotype was inheritable,
mutant mice were outcrossed to wild-type (WT) mice to
generate F1 progeny with subsequent intercrossing of the
resultant F1 mice to generate F2 progeny. Both F1 and F2
mice were examined by indirect ophthalmoscopy or ERG.
If F1 mice were aﬀected, the pedigree was designated as
segregating a dominant mutation. If F1 mice were not
aﬀected but ∼25% of F2 mice were aﬀected, the pedigree
was designated as segregating a recessive mutation. Once the
observed ocular phenotype was determined to be genetically
heritable, mutants were bred and maintained in the Research
Animal Facility at JAX. Mice were provided with NIH
6% fat chow diet and acidiﬁed water, with 12:12 hour
dark:light cycle in pressurized individual ventilation caging
which are monitored regularly to maintain a pathogen-free
environment. Procedures utilizing mice were approved by
the Institutional Animal Care and Use Committee.
2.2. Clinical Evaluation and Electroretinography. Mice, dark
adaptedforaminimum of1hour,weretreatedwithatropine
prior to examination by indirect ophthalmoscopy with a
60 or 78 diopter aspheric lens. Fundus photographs were
taken with a Kowa small animal fundus camera using a
Volk superﬁeld lens held 2 inches from the eye as previously
described [2].
For electroretinographic evaluation of mutants, follow-
ing a 2-hour dark adaptation, mice were anesthetized with
an intraperitoneal injection of xylazine (80mg/kg) and
ketamine (16mg/kg) in normal saline. Additional anesthetic
was given if akinesia was inadequate. The equipment and
protocol used here were those previously described [21].
Brieﬂy, dark-adapted, rod-mediated ERGs were recordedJournal of Ophthalmology 3
with the responses to short-wavelength ﬂashes over 4.0-log
unit to the maximum intensity by the photopic stimulator.
Cone-mediated ERGs were recorded with white ﬂashes
after 10min of complete light adaptation. The signals were
sampled at 0.8msec intervals and averaged.
2.3. Genetic Mapping. Genomic DNA was isolated from tail
tips using a PBND (PCR buﬀer with nonionic detergents)
preparation, which was adapted from a protocol from Perkin
Elmer Cetus [22]. Tail tips were digested in PBND buﬀer +
ProteinaseK overnight at55
◦C. Samples wereheated to 95
◦C
for 10 minutes, and 1μL of the DNA preparation was used
in a 12μL PCR reaction. Amplicons were visualized with
ethidium bromide after electrophoretic separation on a 4%
agarose gel.
For mapping purposes, phenotypically aﬀected mice,
presumed to be homozygous for the mutations, were mated
with DBA/2J mice. The resulting F1 oﬀspring were inter-
crossed to generate F2 oﬀspring if recessive and backcrossed
(BC) to WT parental if dominant. Resulting progeny were
phenotyped by indirect ophthalmoscopy. DNA isolated from
tail tips from a minimum of 10 aﬀected and 10 unaﬀected
mice was pooled and subjected to a genome-wide scan
using 48–80 simple sequence length polymorphic markers
distributed throughout the genome. Samples used in the
DNA pools were tested individually to conﬁrm the map
location [23].
2.4. Preparation of RNA Samples and Subsequent Analysis.
Total RNA was isolated from whole eyes and brains of
aﬀected mutants and B6 mice using TRIzol Reagent (Life
Technologies) per manufacturer’s protocol. Total RNA was
treated with RNase-free DNaseI (Ambion) and quantity was
determined using a NanoDrop spectrophotometer (Thermo
Scientiﬁc). RNA quality was evaluated with an Agilent
Technologies 2100 Bioanalyzer. cDNA was generated using
the Retroscript kit (Ambion).
Primers to sequence the coding region of the candidate
genes were designed from exon sequences obtained from
the Ensembl Database. RT-PCR was done using eye cDNA
in a 24μL PCR reaction containing 1xPCR buﬀer (10mM
Tris-HCl pH 8.3, 50mMKCl), 250μM of each dATP, dCTP,
dGTP, dTTP, 0.2μMo fe a c hf o r w a r da n dr e v e r s ep r i m e r ,
1.5mMMgCl2, and 0.6U Taq polymerase. The following
PCR program was used: 94
◦C for 1 minute 30sec followed
by 35 cycles of 94
◦C for 30sec, 55
◦C for 45sec, and 72
◦C
for 45sec, and a ﬁnal extension of 72
◦Cf o r2m i n u t e s .
PCR products were electrophoresed on a 1% agarose gel and
visualized by ethidium bromide staining. DNA fragments
were sequenced on an Applied Biosystems 3730XL (using a
50cm array and POP7 polymer).
2.5. Histological Analysis. Mice were asphyxiated by carbon
dioxide inhalation, and enucleated eyes were ﬁxed overnight
in cold methanol/acetic acid solution (3:1, v/v). The
paraﬃn-embedded eyes were cut into 6μm sections, stained
by hematoxylin and eosin (H and E), and examined by light
microscopy.
3. Results and Discussion
3.1. Status of the EMR Program. Since its inception in the
1980s, the EMR program has identiﬁed and/or imported
more than 100 mouse models with ocular abnormalities
for research. Table 1 lists some of the retinal degeneration
mouse models of human disease developed and/or currently
maintained in the EMR that are available to the Research
Community. Other models are described on the EMR web
page (http://eyemutant.jax.org/).
3.2. Status of the TVRM Program. The TVRM program was
built upon the success of the Neuromutagenesis Facility
(NMF) at The Jackson Laboratory, and 15 of the 60 mutant
lines (Tables 2 and 3) in which a disease phenotype has
been subsequently ﬁxed as a coisogenic inbred strain by the
TVRM program were ﬁrst identiﬁed in screens conducted by
the NMF. The remaining 45 TVRM lines were established
by screening ∼14,000 G3 mice for anterior and posterior
segment abnormalities by indirect ophthalmoscopy and/or
slit lamp biomicroscopy. Six of the 60 mutations (10%) are
inherited in a dominant or codominant manner, and the
remaining are recessive mutations. Forty six of the mutants
haveretinalphenotypesrangingbetweenpan-retinalspotsor
patches, pigmentation defects, and/or attenuation of blood
vessels with or without morphological changes that were
detectable by light microscopy. Six of the mutant lines have
reduced or absent ERG responses for either rod and/or cone
cells without photoreceptor loss. Five mutant lines presented
with vitreal ﬁbroplasia and three with cataracts. Forty six of
the mutations (23 reported in Table 3) have been localized to
a chromosome, and the molecular basis has been identiﬁed
for23ofthem(Table 2).Fourteenlinesarestillintheprocess
of being mapped (data not shown). Nineteen of the 23
mutations in Table 2 were novel alleles in genes in which
mutations had previously been reported. Some of these
mutants are described below. It should be noted that the
current bias for reoccurrences of mutations, herein referred
to as remutations, versus identiﬁcation of novel genes in
Table 2 is probably due to the fact that once a mutation is
mapped, candidate genes previously associated with an eye
disease can be quickly sequenced. Regions containing no
obvious candidate genes need to be narrowed further and/or
all genes within the region may need to be sequenced to
identify the disease-causing mutation.
Interestingly, new phenotypes were observed in 8 of the
remutations that have been examined (see; [51–55], personal
communication PMN). For example, outer segments (OSs)
were either formed abnormally or did not initiate in retinas
from homozygous Rpgrip1nmf 247 mice [51]. This was in
contrast to the Rpgrip1tmlTili targeted null mutant, hereafter,
Rpgrip1
−/− in which OS discs were formed and stacked
vertically rather than horizontally [56]. Targeted alleles of
Lama1 were reported to be embryonic lethal [57, 58].
The ENU-induced allele, Lama1nmf 223, provides a viable,
hypomorphic allele in which abnormalities in the adult
animal could be examined. Clinically, vitreal ﬁbroplasia and
abnormal retinal vasculature were observed. Histologically,4 Journal of Ophthalmology
Table 1: Mouse retinal mutants maintained in the Eye Mutant Resource (EMR) at The Jackson Laboratory.
Model Mode Gene Chr. Clinical phenotype
rd1 AR Pde6b 5 Early onset, severe retinal degeneration [24]
pcd AR Agtpbp1 13 Slower retinal degeneration associated with Purkinje cell degeneration [25]
nr AR UN 8 Progressive retinal degeneration with hyperactive ataxic behavior (nervous) [25]
Rd2 AD Prph2 17 Slow progressive retinal degeneration [26]
rd3 AR Rd3 1 Retinal degeneration, beginning at 3 weeks of age [27]
Rd4 AD Gnb1 4 Autosomal dominant retinal degeneration [28]
Tub AR Tub 7 Retinal degeneration, hearing loss, and late-developing obesity, also known as rd5 [29]
mnd AR Cln8 8 Early onset retinal degeneration with a late-onset progressive motor neuron degeneration [30]
rd6 AR Mfrp 9 Small, white retinal spots and progressive photoreceptor degeneration [31]
rd7 AR Nr2e3 9 Retinal spots and progressive photoreceptor degeneration [32]
rd8 AR Crb1 1 Focal photoreceptor degeneration [33]
Rd9 XD UN X Progressive retinal white spotting and degeneration [33]
rd10 AR Pde6b 5 Early onset, mild retinal degeneration [34]
rd11 AR Lpcat1 13 Retinal degeneration with white retinal vessels at 4 weeks of age [35]
rd12 AR Rpe65 3 Poor ERG response and late onset retinal degeneration [36]
rd14 AR UN 18 Slow retinal degeneration with white retinal spots [37]
rd15 AR UN 7 Retinal degeneration with retinal outer plexiform dystrophy [38]
rd16 AR Cep290 10 Early onset retinal degeneration [39]
rd17 AR Gnat1 9 Poor rod ERG response and slow retinal degeneration [40]
cpﬂ1 AR Pde6c 19 Cone photoreceptor function loss-1 [41]
Cpﬂ2 AD UN 3 Cone photoreceptor function loss-2 with white retinal spots [42]
cpﬂ3 AR Gnat2 3 Cone photoreceptor function loss-3 [43]
Cpﬂ4 AD UN 17 Cone photoreceptor function loss-4 [44]
cpﬂ5 AR Cnga3 1 Cone photoreceptor function loss-5 [45]
cpﬂ6 AR Hcn1 13 Cone photoreceptor function loss-6 [46]
cpﬂ7 AR UN 19 Cone photoreceptor function loss-7 [47]
nob2 XR Cacna1f X Anatomical and functional abnormalities (no b-wave-2) in the outer retina [48]
nob3 AR Grm6 11 Retinal functional abnormalities (no b-wave 3) [49]
arrd2 AR Mdm1 10 Age-related retinal degeneration-2 [50]
AR: autosomal recessive, AD: autosomal dominant, XR: X-linked recessive, UN: unknown.
persistenthyaloidvesselsandﬁbroustissuewerefoundinthe
vitrealspace,andtheinnerlimitingmembranewasdisrupted
[52]. In an allelic series of mutations within the rhodopsin
gene, light-induced retinal degeneration was observed. Het-
erozygous Rho
Tvrm1 and Rho
Tvrm4 mice raised in standard
vivarium lighting did not exhibit any morphological changes
until exposed to bright light [54]. Previously Rho alleles
showed spontaneous and pan-retinal degeneration, even
when mice were reared from birth in darkness [59].
3.3. New Alleles of Crxtvrm65, Rp1tvrm64,a n dRpe65tvrm148
3.3.1. Crxtvrm65. tvrm65 segregates as a recessive muta-
tion that is characterized by a pan-retinal, grainy fundus
appearance that eventually progresses with age to patches
of depigmentation within the central retina (data not
shown). The mutation was mapped to chromosome (Chr.)
7 between ﬂanking markers D7Mit75 and D7Mit190.A
single nucleotide polymorphic (SNP) marker (SNP ID:
RS13479126) served to narrow the interval. Crx, a reasonable
biological candidate gene, contained within the minimal
interval, was examined for a mutation.
CRX is an evolutionary conserved protein. Mice and
humans share a 97% sequence similarity. To date, two Crx
t r a n s c r i p t sh a v eb e e nr e p o r t e d .T h el o n gi s o f o r m( G e n b a n k
nm 001113330) has 25 additional amino acids (aa) in
its N terminus when compared to the shorter isoform
(Genbanknm 007770).AT>Anonsensemutationidentiﬁed
inCrxtvrm65 islocatedinthelastexonandisexpectedtoaﬀect
both isoforms. The tvrm65 mutation is predicted to cause an
early termination at Leu277 (TTG) of the 323aa from the
longer isoform or at Leu253 of a 299aa product from the
shorter isoform (Figure 2(a)).
Phenotypically, Crxtvrm65 mutants resemble the null
mouse model in which the single homeodomain containing
region [60]o fCrx was targeted. Homozygous CrxtmlClc mice
do not develop OS and photoreceptors degenerate. Crxtvrm65
mutants show a rapid photoreceptor degeneration (Figure
2(b)). At postnatal day (P) 14 and P21, OSs were absent
and inner segments (ISs) were rarely observed (Figure 2(b)).
By P21, photoreceptor cell bodies were reduced to ∼60% ofJournal of Ophthalmology 5
Table 2: Mouse mutants from the Translational Vision Research Models (TVRMs) program in which the molecular basis for the disease
phenotype has been identiﬁed.
Model Mode Gene Chr. Clinical phenotype
tvrm64 AR Rp1 1 Juvenile onset retinal degeneration
nmf12 AR Mertk 2 Late onset slow degeneration
tvrm148 AR Rpe65 3 Late onset retinal degeneration
nmf192 AR Nphp4 4 Early rapid retinal degeneration
nmf364 AR Pde6b∗ 5 Early rapid retinal degeneration
nmf449 AR Pde6b∗ 5 Early rapid retinal degeneration
Tvrm1 AD Rho 6 Light inducible retinal degeneration [51]
Tvrm4 AD Rho 6 Light inducible retinal degeneration [51]
Tvrm144 AD Rho 6 Light inducible retinal degeneration
tvrm65 AR Crx 7 Early rapid retinal degeneration
tvrm27 AR Trpm1 7N o B - w a v e
tvrm89 AR Myo6 9A t t e n u a t e d E R G
tvrm84 AR Grm1 10 Attenuated ERG
nmf246 AR Uchl3 14 Juvenile onset retinal degeneration
nmf247 AR Rpgrip1 14 Early rapid retinal degeneration [52]
nmf5a AR Pfnd5 15 Early rapid retinal degeneration
nmf240 AR Clcn2 16 Early rapid retinal degeneration [53]
nmf223 AR Lama1 17 Vitreal ﬁbroplasia, vascular abnormalities [54]
tvrm124 AR Tulp1∗ 17 Early rapid retinal degeneration
nmf282 AR Pde6a 18 Early rapid retinal degeneration [55]
nmf363 AR Pde6a 18 Early rapid retinal degeneration [55]
tvrm58 AR Pde6a∗ 18 Early rapid retinal degeneration
tvrm32 AR Hps1∗ 18 Pigmentation defect
∗Established by complementation testing.
Table 3: Mouse mutants from the Translational Vision Research Models (TVRMs) program in which the molecular basis of the disease
phenotype has not yet been identiﬁed.
Model Mode Chr. Clinical phenotype
tvrm9 AR 1 Retinal spots
tvrm113 AR 4 Retinal spots, grainy fundus appearance
Tvrm6 AD 7 Retinal spots
tvrm116 AR 12 Retinal spots, late onset
tvrm111 AR 14 Retinal spots
nmf289 AR 16 Retinal spots
tvrm5 AR 18 Retinal spots in central retina
tvrm10 AR 19 Retinal spots, coloboma, and vascular defects
tvrm77 AR 6 Central patches
tvrm119 AR 18 Retinal patches
tvrm127 AR 18 Retinal patches
tvrm102 AR 6 Grainy retina
tvrm101 AR 10 Grainy retina
nmf67 AR 7 Fine web-like fundus appearance
Tvrm122 AD 3 Shiny ﬂecks
tvrm64a AR 12 None, identiﬁed through histology, lamination defect
tvrm111b AR 8 Abnormal ERG
tvrm87 AR 4 Vitreal ﬁbroplasia
tvrm114 AR 4 Vitreal ﬁbroplasia, cataracts
tvrm53 AR 7 Vitreal ﬁbroplasia
tvrm85 AR 18 Vitreal ﬁbroplasia
Tvrm49 AD 15 Cataracts
tvrm129 AR 13 Cataracts6 Journal of Ophthalmology
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Figure 2: The mouse model Crx
tvrm65. (a) The mutation in
homozygous Crx
tvrm65 causes a premature termination at aa residue
Leu277. The mutated nucleotide is highlighted (b). Histology of
control and Crx
tvrm65 mutant retina at P14, P21, and 3 months
of age. OSs were absent at all ages in homozygous Crx
tvrm65,a n d
progressive thinning of IS, ONL, and OPL was observed. OSs: outer
segments,ISs:innersegments,ONL:outernuclearlayer,OPL:outer
plexiform layer, INL: inner nuclear layer. Scale bar = 20μm.
controls. The outer plexiform layer (OPL) was also thinner,
approximately 40% of controls. By 3 months of age, the OSs
and ISs were absent and only 2∼3 layers of outer nuclear
layer(ONL)wereremained.Thephotoreceptordegeneration
observed in the Crxtvrm65 mutants occurs more rapid than
reported for the null allele [60]. This may, in part, be due
to the diﬀerence in genetic background of the two alleles as
Crxtvrm65 was generated on a B6 background, whereas the
previous null allele was described on a segregating B6 and
129Sb genetic background.
3.3.2. Rp1tvrm64. tvrm64 segregates as a recessive mutation
that is characterized by a grainy fundus appearance and
attenuated retinal vessels (data not shown). The mutation
mapped to Chr.1 between the centromere and D1Mit427,a n
interval in which Rp1 resides. Rp1 e n c o d e sal a r g ep r o t e i n
of 2095aa in mouse and 2156aa in humans. RP1 localizes
in the connecting cilia and appears to play a structural
and/or functional role in molecular transport through the
connecting cilia [61, 62]. Mouse RP1 shares 72% similarity
with human RP1. Structurally, it has two ubiquitin homolog
(UBQ) domains in its amino terminus. Rp1 was tested for a
mutation, as the phenotype of homozygous Tvrm64 mutants
wassimilartothatofmicecarryingeitheroftwotargetedRp1
alleles, involving homologous recombination in which exons
2a n d3w e r et a r g e t e d( Rp1tm1Jn2)[ 61]o rat r u n c a t i o na f t e r
codon 662, Rp1tm1Eap, analogous to the R667ter mutation in
humans [62]. Direct sequencing of homozygous Rp1tvrm64
retinal cDNA revealed an A>T transversion at nucleotide
1769 (Genbank nm 011283), creating a nonsense mutation
in which Arg522 (AGA) is changed to a termination codon
(TGA;Figure 3(a)). The mutation is localized adjacent to the
two UBQ domains in RP1.
T h eO Sl e n g t ho fRp1tvrm64 mutant retina was approx-
imately 50% shorter than WT controls at 1 month of age
(Figure 3(b)). The diﬀerence in IS length between mutant
and controls, however, was barely discernable at 1 month
of age but was obviously shorter in Rp1tvrm64 mutants
at 3 months of age. The photoreceptor degeneration was
progressive with little diﬀerence in cell body number in the
ONL at 1 month of age but by 3 months, cell nuclei were
reduced to ∼50% in mutants in comparison to controls.
In contrast, the photoreceptor morphology of Rp1tm1Jn2
mice [61] appeared normal by light microscopy at P30 with
comparable length of OS in mutant and controls. Also,
Rp1tm1Eap mice [62] at P30 showed shorter OS lengths
and a 1–2-layer reduction in ONL. Therefore, the disease
progression in Rp1tvrm64 at similar age appears to be more
severe than observed in Rp1tm1Jn2 mice but less severe than
Rp1tm1Eap mice.
This diﬀerence between the models was also discernable
functionally. At 1 month of age, dark-adapted ERGs of
Rp1tvrm64 mice were comparable to WT (Figures 3(c)
and 3(d)). In Rp1tm1Eap, these responses were signiﬁcantly
reduced at 4∼5w e e k so fa g e[ 62].
3.3.3. Rpe65tvrm148. The recessive tvrm148 mutation is char-
acterized by late onset retinal spotting and by patchesJournal of Ophthalmology 7
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Figure 3: The mouse model Rp1
tvrm64. (a) Direct sequencing of control and Rp1
tvrm64 homozygous mutant identiﬁed an A to T mutation,
predicting early termination at Arg522. The position of the mutation is highlighted and an asterisk indicates the termination. (b) The retinal
morphology of control and Rp1
tvrm64 mice was examined at 1 and 3 months of age (mo). OSs: outer segments, ISs: inner segments, ONL:
outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer. Scale bar = 20μm.(c) Electroretinogram ofdark-adapted (scotopic)
and light-adapted (photopic) control at 9 weeks of age and Rp1
tvrm64 at 4 weeks of age. (d) The amplitude of dark-adapted a and b-wave and
light-adapted b-wave (±SEM, n = 3) of 4 weeks old Rp1
tvrm64 mice and age matched controls.
of depigmentation that is readily discernable by indirect
ophthalmoscopy at 5 months of age (data not shown). The
mutation mapped to Chr. 3 between markers, D3Mit147
and D3Mit19. Rpe65 was screened by direct sequencing for
a mutation as it fell within the minimal interval identiﬁed,
and the disease phenotype was similar to that reported
for the Rpe65tmlTmr targeted knockout animal (herein
referred to as Rpe65
−/−)[ 63]a n dRpe65rd12 [64]a l l e l e s .
AT >C point mutation was found by direct sequencing
of retinal cDNA from Rpe65tvrm148 mice and is expected
to generate a mutant protein with an F229S point muta-
tion (Figure 4(a)). F229 is evolutionarily conserved from8 Journal of Ophthalmology
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Figure 4: The Rpe65
tvrm148 mouse model. (a) Mutation analysis by direct sequencing revealed that the homozygous Rpe65
tvrm148 mouse
harbored a missense mutation at aa residue 229, causing an amino acid change from Phe to Ser. The highlighted nucleotide indicates the
mutation in the Rpe65
tvrm148 mouse (left). RPE65 protein is an evolutionarily conserved protein, and F229 is a nearly invariant residue from
human to zebra ﬁsh (right). (b) Retinal morphology at 1 and 4 months and 1 year of age was analyzed by light microscopy. ONL thinning
was progressive, and IS/OS was shorter than controls at all ages examined. OSs: outer segments, ISs: inner segments, ONL: outer nuclear
layer, OPL: outer plexiform layer, INL: inner nuclear layer. Scale bar = 20μm. (c, d) Physiological retinal function was analyzed by ERG at
4 weeks (c) and 17 weeks of age (d). The plotted amplitude was obtained at 9 weeks from control and Rpe65
tvrm148 m i c e( c )o ra t1 7w e e k s
from control and from homozygous Rpe65
tvrm148 mice. N = 3.Journal of Ophthalmology 9
humans to zebra ﬁsh but interestingly not in chimpanzee
(Figure 4(a)).
The Rpe65tmlTmr mutant [63] had a nonfunctional rod
ERG response due to the lack of 11-cis-retinal production
in the RPE and showed disorganized rod outer segments.
Another targeted allele mimicking a human R91W mutation
was found in Leber Congenital Amaurosis (LCA2) patients
(Rpe65tmlLreb)[65],andaspontaneousmodelRpe65rd12 [64]
showed a similar disease progression to that observed in
Rpe65tvrm148 mutants. Photoreceptors degenerated progres-
sively in homozygous Rpe65tvrm148 mouse from 1 month to
1 year of age, the latest time point examined (Figure 4(b)).
At 1 month of age, OS and IS lengths were approximately
50% shorter than controls with no obvious thinning of the
ONL. The photoreceptor nuclei were reduced in thickness by
∼20% at 4 months and ∼60% by 1 year of age.
Like the three previously reported mouse models,
Rpe65tvrm148 e x h i b i t e ds e v e r e l yi m p a i r e dr o dE R G sa n d
relatively spared cone ERGs. Rod responses were absent by 4
w e e k so fa g e .H o w e v e r ,c o n eb - w a v eE R G sw e r ec o m p a r a b l e
to controls at 4 weeks of age but by 17 weeks, the amplitudes
were reduced compared to controls (Figures 4(c)–4(d)).
4. Conclusions
4.1. The Utility of Spontaneous and Chemically Induced
Mutations. Spontaneous or chemically induced mutations
in mice provide a rich source of animal models. These
mutations oﬀer some advantages for the study of human
genetic diseases and basic gene function over mutations
obtained by homologous recombination. First, these muta-
tions are generally identiﬁed because they cause a clinically
relevant phenotype. By starting with a known phenotype,
information about the physiological function of the mutant
gene and its biomedical relevance is immediate. Second, the
forward genetic approach has the potential for discovery of
new genes involved in ocular development and function that
were previously unappreciated. Further, spontaneous and
chemically induced mutations may better model naturally
occurring human genetic conditions. They produce a full
and unbiased array of mutation types—single base pair
changes or deletions, and in the case of spontaneous
mutations, retroviral insertions, repeat sequence expan-
sions, and chromosomal rearrangements. These mutations
can create alternatively spliced transcripts or nonsense or
missense reading frames. They can abolish all protein
function (null), partially diminish function (hypomorphic),
orchangefunction(dominantnegativeorgain-of-function).
Moreover, allelic series—collections of mutant alleles of the
same gene—can provide domain speciﬁc information about
protein function and information on alternatively spliced
variants. Biomedically relevant phenotypes associated with
some human genetic disorders may be revealed by the
diﬀerent alleles that are not replicated by knockout alleles.
For example, whereas the null alleles of Lama1 [57, 58]
were embryonic lethal, the hypomorphic ENU nmf223 allele
allowed for the examination of ocular phenotypes in adult
mice [52]. In another example, the rd10 allele of Pde6b [66]
identiﬁed by the EMR program has a later onset and slower
rateofdegenerationthantheoriginalrd1allele,thusallowing
fortheopportunitytotesttherapeuticstrategies[67].Finally,
two phosphodiesterase 6a mutations ﬁrst described by the
TVRMprogramcausemissensemutationsthatleadtodiﬀer-
ent biochemical outcomes and rates of photoreceptor degen-
eration, suggesting a diﬀerence in the importance of the par-
ticular mutant residues to the function of the protein [55].
It should also be noted that spontaneous mutations
occur on a wide variety of strain backgrounds, and chem-
ical mutagenesis can be carried out in diﬀerent genetic
backgrounds. The observation of altered mutant phenotypes
in diﬀerent genetic backgrounds can provide a means for
identifying interacting genes and molecular pathways of
pathophysiology. For example, Nr2e3rd7 was observable
clinically only in the B6 genetic background [68], and
a number of genetic backgrounds act to ameliorate the
disease [69]. Crb1
rd8 is observable clinically in the C3H/HeJ
background but not in the B6 background [70], and the
null mutation is phenotypically diﬀerent on a segregating
129X1/SvJ and B6 background [71]. Finally, a wide variety
of disease phenotypes are observed in rd3 [27]a n dGnb1
rd4
[28]i nd i ﬀerent strain backgrounds, indicating interactions
with genetic background modiﬁers. The variation in genetic
background enables discovery of modiﬁers and gene interac-
tions and could be essential to the discovery of important
mutant phenotypes and potential targets for therapeutic
intervention.
4.2. The Future of the EMR and TVRM Programs. In the
future, the EMR will continue to screen for spontaneous
mutations in the large production colonies at The Jackson
Laboratory. The mutants identiﬁed in the TVRM program
will be incorporated into the EMR distribution colonies as
the molecular bases of the mutations are identiﬁed. Finally,
sensitized chemical mutagenesis screens are planned that
will uncover pathways important in retinal development,
maintenance, and function.
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